What is the hidden buying committee?

The hidden buying committee is the group of stakeholders who hold veto power over a B2B purchase but never engage with your marketing: Legal, IT, Procurement, Finance and, in healthcare, Clinical review. Research from the LinkedIn B2B Institute with Bain places roughly half of all buying influence with people who never take the sales call, yet can stall or kill the deal.

Why do healthcare B2B deals stall after a strong pitch?

A deal rarely dies with the buyer in the room. It dies in review, where stakeholders who never met you cannot tell you apart from competing vendors. In healthcare, sameness across brands reads as risk to a cautious committee, so the safe decision is to ask for more time. The pitch was fine. The brand was not defensible to the people who finish the purchase.

What is Buyability in brand strategy?

Buyability is how ready a brand is to be bought, not just seen, across the full buying committee rather than only the economic buyer. A brand the whole committee trusts lowers the risk a qualified deal dies in review, which reframes brand from a soft marketing cost into deal risk insurance. Buyability as a framework is attributed to the LinkedIn B2B Institute with Bain.

Your Brand Isn't Losing in the Pitch. It's Losing in the Room the Hidden Buying Committee Decides In.

Jul 28
4 min read

It's losing because you never were invited.

Think about the last deal you lost. Not the one that never had a pulse. The good one, where the demo went well and your champion was genuinely excited, the follow-up questions were sharp, and then it went quiet. You told yourself the timing slipped or the budget moved. You almost certainly told yourself the wrong story.

That deal did not die in the room with you. It died in a room you were never invited to, in a conversation you never got to hear, held by people who never took your call.

The deal did not die in the room with you. It died in a room you were never invited to.

This is the part of healthcare brand strategy almost nobody accounts for, and it is the part that decides most outcomes. We build brands for the buyer we can see: the marketing lead, the clinical director, the person who takes the meeting and nods along. Then we act surprised when the deal stalls somewhere we have no visibility, raised by someone we never designed a single word for.

The buyer you designed for is not the buyer who decides, the Hidden Buying Committee.

The uncomfortable data has been sitting in plain sight for years. Research from the LinkedIn B2B Institute with Bain puts roughly half of all buying influence in the hands of people who never engage with your marketing at all. These are the stakeholders in Legal, IT, Procurement, Finance and, in healthcare, Clinical review. I call them the Hidden Buying Committee, because their defining feature is not their seniority. It is their invisibility to you.

Circular diagram of a healthcare B2B buying committee arranged around a central node labeled The Deal. Six stakeholders shown in purple as the ones marketing reaches: Champion, End User, Economic Buyer, Clinical Lead, and two others. Six shown in grey as the hidden stakeholders where deals die: Finance, Legal and Regulatory, Procurement, IT and Security. The split shows that half the deciding committee is never reached by traditional marketing.

They hold veto power and they never show up in your funnel. Your champion can love you completely and still watch the deal die on a desk two doors down, because the person at that desk had one question your brand never answered and read the silence as risk.

The same body of research is blunt about what this costs. Buyers are far more likely to purchase, on the order of 20 times, when the full buying group already knows the brand, not just the individual taking the meeting. And most buyers, more than 70%, end up choosing whoever was first on their shortlist. The committee you cannot see is doing the shortlisting, and it is doing it long before your sales cycle formally begins.

Why healthcare makes this worse.

Every complex B2B category has a hidden committee. Healthcare has that plus a second problem that compounds it, and it is the one I find most brands refuse to look at directly. Open the websites of 10 companies in any healthcare category and you will see the same thing: the same blues, the same abstract promises about partnership and outcomes, the same competent, careful, interchangeable voice. I call this Clinical Monotony, and it is not an aesthetic complaint. It is a commercial liability.

When every option in a category looks and sounds the same, sameness itself becomes the signal, and the signal it sends to a risk-averse committee is that you are indistinguishable from the alternatives and therefore substitutable. A procurement lead who cannot articulate why you are different has no argument to carry you upward, so they do the safe thing and ask for more time. That is not a design failure your marketing team feels. It is a deal your sales team loses without ever knowing why.

When every option looks the same, sameness becomes the signal, and it reads as risk to the people who decide.

Brand is not a marketing cost. It is deal risk insurance.

Here is the reframe that changes how the rest of the committee treats this. For a chief financial officer, brand is a soft cost with no number attached, which is exactly why it loses every budget fight to something that has one. But that framing is wrong, and the research shows why.

A brand the whole committee already trusts is not a decoration. It is the mechanism that lowers the probability a qualified deal dies in review. That is a risk position, not a marketing expense, and it deserves the name I give it: Deal Risk Insurance. Framed that way, brand itself stops competing with performance marketing for budget and starts competing with every other thing the company does to de-risk revenue, which is a fight it can actually win.

The test I hold every healthcare brand to is simple: if your brand is not defensible to a chief financial officer, it is not buyable. Not unattractive. Not off-strategy. Not buyable, because the people who finish the purchase cannot build a case for you they are willing to sign their name to.

You cannot fix a room you cannot see.

The hard part is not agreeing with any of this. Most leaders, once they see it, recognize their own lost deals immediately. The hard part is that the committee is, by definition, invisible to you. You cannot interview the procurement lead who stalled you. You cannot ask the IT reviewer what gave them pause. You get silence, and silence tells you nothing about which objection to answer or which perception to close.

This is the specific problem I built nunNEO to solve. It is a brand diagnostic that reads how ready a brand is to be bought across the full committee, not just the buyer in the room, and it surfaces the stakeholders who quietly kill deals along with the objections they raise, in their own voice. It does not replace strategic judgment, and it is not built to make anything faster. It exists to make the invisible room legible, so that for once you can see what your team cannot and answer it before it costs you the next deal.

That is the whole argument for taking brand seriously in this category, and it has nothing to do with taste. In healthcare, trust moves slowly and the people who grant it mostly do so out of your sight. A brand that has done the work is simply the one that survives the room you never get to enter. If you want to see what that room looks like for your own brand, reply and we will book a Brand Clarity Call.

Philipp Striebe is the founder of STR3, a brand strategy studio for healthcare and complex B2B, and the creator of nunNEO. Signal > Noise is his series on building brands that earn trust in categories where trust decides everything.

Buyability research attributed to the LinkedIn B2B Institute with Bain.